Olympus Cuts Full-Year Guidance as Profit Slides Despite Stable Revenue

Olympus ( (JP:7733) ) has issued an announcement.

Olympus reported nine-month revenue to December 31, 2025 of ¥715.4 billion, down 1.4% year on year, with operating profit dropping 35.4% and profit attributable to owners of the parent falling 43.2%, reflecting weaker profitability in its continuing operations. Despite the earnings decline, total assets and equity both increased modestly, the company maintained a zero interim dividend but kept its full-year dividend forecast of ¥30 per share, and it revised its full-year earnings guidance downward while presenting results in ranges, signaling a more cautious outlook for fiscal 2026 amid ongoing portfolio adjustments and the addition of Swan EndoSurgical, Inc. as an equity-method affiliate.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2140.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

More about Olympus

Olympus Corporation is a Japan-based medical technology company listed on the Prime Market of the Tokyo Stock Exchange. The group focuses on endoscopic and other minimally invasive medical systems, having classified its Orthopedic Business as a discontinued operation as it sharpens its core portfolio in therapeutic and diagnostic solutions.

Average Trading Volume: 3,099,279

Technical Sentiment Signal: Hold

Current Market Cap: Yen2174.2B

Find detailed analytics on 7733 stock on TipRanks’ Stock Analysis page.